Barry Cohen

Barry Cohen

Barry Cohen has nearly 30 years in communications and marketing, the majority in senior positions at three large international health care companies – Abbott Laboratories, Warner-Lambert (now part of Pfizer) and Bayer, Inc.

At Abbott, Cohen was a member of the company’s investor relations team, responsible for preparing all financial analyst presentations. He also oversaw the company’s award-winning annual and quarterly reports and was responsible for both the company’s investor seminar and annual shareholders’ meeting.

After relocating to Arizona, Cohen served as editor of M.D. News, a magazine for Phoenix-area physicians. Later he was a reporter for a weekly newspaper in a north Phoenix, where he specialized in business articles and profiles of local publicly traded companies.

To further his knowledge and understanding of financial markets, Cohen earned a series 7 broker’s license and was employed at Charles Schwab as a registered representative.  He returned to the communications field with CPRi Communications, where he wrote numerous case studies and bylined articles for the company’s clients in the health care information technology industry. Later, he worked for a Scottsdale, Ariz.-based investment bank preparing profiles of companies being offered for sale.

Recent Articles

Health Care Companies Slow On the Social-Media Draw

Businesses are too worried about FDA pushback.

ObamaCare Court Test a Non-event for Health Stocks

Health insurance, pharmaceutical companies' gains show confidence that ObamaCare is all but a done deal.

‘Cloudy’ Outlook Is Good News for PerkinElmer

PerkinElmer taking a bigger slice of the cloud, acquires Geospiza to bolster life sciences business.

Targacept Faces a Lonely Road

The company loses financial help on drug development.

Investors Haven’t Lost Heart in Pacemaker Stocks

A study's warning about the devices comes -- and goes.

AstraZeneca Plagued By Purple Pill Problems

The company faces eroding sales of its blockbuster drugs.

Bristol-Myers’ Near Term Rides on Blood Thinner Study

It's likely sink-or-swim later this month when results are announced.

Health Care Stocks — You Still Have to Be Smart

Even in this booming sector, it pays to stick to best investing practices.

BioMimetic Has Suitors Lying in Wait

A key FDA OK could have the buyout offers rolling in.

Mead Johnson’s Margins Are Making Abbott Jealous

The profit war is on between the top baby forumula makers.